ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has been given an average recommendation of “Buy” by the six brokerages that are covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $22.75.
A number of equities analysts have issued reports on the company. Cantor Fitzgerald assumed coverage on ARS Pharmaceuticals in a report on Tuesday, August 20th. They issued an “overweight” rating and a $30.00 target price for the company. Leerink Partners upped their price objective on ARS Pharmaceuticals from $19.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday, August 12th. Finally, Raymond James upgraded shares of ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $18.00 to $22.00 in a research report on Tuesday, August 13th.
Read Our Latest Stock Report on ARS Pharmaceuticals
Insider Transactions at ARS Pharmaceuticals
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. RA Capital Management L.P. grew its position in shares of ARS Pharmaceuticals by 14.8% in the 1st quarter. RA Capital Management L.P. now owns 10,860,977 shares of the company’s stock worth $110,999,000 after buying an additional 1,401,299 shares during the last quarter. Vanguard Group Inc. lifted its position in ARS Pharmaceuticals by 37.0% during the 1st quarter. Vanguard Group Inc. now owns 2,886,455 shares of the company’s stock valued at $29,500,000 after acquiring an additional 779,969 shares during the period. ClariVest Asset Management LLC purchased a new stake in shares of ARS Pharmaceuticals in the first quarter worth $2,790,000. Jacobs Levy Equity Management Inc. raised its holdings in ARS Pharmaceuticals by 1,280.5% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 277,706 shares of the company’s stock worth $2,838,000 after acquiring an additional 257,589 shares during the last quarter. Finally, Franklin Resources Inc. lifted its stake in ARS Pharmaceuticals by 5.9% during the 4th quarter. Franklin Resources Inc. now owns 4,098,497 shares of the company’s stock valued at $22,460,000 after acquiring an additional 229,988 shares during the period. 68.16% of the stock is currently owned by hedge funds and other institutional investors.
ARS Pharmaceuticals Stock Performance
Shares of ARS Pharmaceuticals stock traded up $0.24 during midday trading on Tuesday, hitting $13.20. 876,687 shares of the company traded hands, compared to its average volume of 715,928. The firm’s fifty day moving average price is $10.43 and its 200-day moving average price is $9.36. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -24.92 and a beta of 0.87. ARS Pharmaceuticals has a 12 month low of $2.55 and a 12 month high of $16.50.
ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The business had revenue of $0.50 million for the quarter, compared to analysts’ expectations of $2.00 million. Equities research analysts forecast that ARS Pharmaceuticals will post -0.66 earnings per share for the current year.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
Featured Articles
- Five stocks we like better than ARS Pharmaceuticals
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Why the Buy-and-Hold Strategy May Be Best for Most Investors
- Market Cap Calculator: How to Calculate Market Cap
- Eli Lilly’s Path to the Next Trillion Market Capitalization
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Mobileye Global: CEO Makes $10 Million Bet on Future Strength
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.